Telix Pharmaceuticals - Another buyout of related assets
The world of prostate imaging received a shake-up with the recent US$450m buyout offer for Blue Earth from Bracco. Blue Earth’s revenue derives primarily from its prostate imaging agent, Axumin (US$140m Q1–Q319, according to Bracco), which we expect to offer competition for illumet. Blue Earth is also developing a PSMA positron emission tomography (PET) agent, although it is only in Phase I. Serendipitously, a study was recently initiated at Emory University to investigate Axumin vs illumet in a 140-person, head-to-head study.Telix Pharmaceuticals Ltd. Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.